Eda Eylemer Mocan, Medical oncologist at Ankara university, shared a recent article by Daniel P. Petrylak on X:

“TROPHY-U-01 Cohort 2
SG in Metastatic Urothelial Cancer

Cisplatin-Ineligible
Progressing after ICI

Med f/u 9.3 m, ORR 32%, DOR 5.6 m
Grade ≥3 AE 87% of pts
Neutropenia 34%
Anemia 24%
Fatigue 18%
Diarrhea 16%

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Authors: Daniel P. Petrylak, MD, Scott T. Tagawa, MD, Rohit K. Jain, MD, Manojkumar Bupathi, MD, Arjun Balar, MD,Arash Rezazadeh Kalebasty, MD, Saby George, MD and Petros Grivas, MD, PhD

Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Source: Eda Eylmer Mocan/X